2017_SBRT_Course Book
Local tumor control after spine SBRT
Study
# Pat / Tx
FU (months)
SBRT Dose
Local control
Ryu 2004 Henry Ford Hospital
49 / 61
6 – 24
1 x 10-16Gy
84% @ 1a
Gerszten 2007 Pittsburgh Chang 2007 M. D. Anderson Yamada 2008 MSKCC
49 / 65
Median 21
1 x 12.5 - 25Gy
90%
38 / -
Median 21
6 x 5Gy, 3 x 9Gy
84% @ 1a
93 / 103
Median 15
1 x 18 – 24Gy
90% @ 2a
Guckenberger 2009 Würzburg
14 / 16
Median 17
20 x 3Gy
89% @ 2a
Sahgal 2009 PMH / Stanford
14 / 23
Median 9
3 x 8Gy
78%
Balagamwana 2012 Cleveland Clinic
57 / 85
Median 5.4
1 x 15Gy
71% @ 1a
Garg 2012 M. D. Anderson
61 / 63
Median 20
1 x 16-24Gy
88 @ 1.5a
MF: 96% @ 2a SF: 70% @ 2a
Heron 2012 Pittsburgh and Georgetown Schipani 2012 Henry Ford Hospital
228 / 348
Median 12
1 – 5 Fx
124 / 165
Median 7
1 x 18Gy
ESTRO SBRT 2017 - Matthias Guckenberger
07.09.17
33
/
DOSIS: a multi-center phase II trial
Prospective phase II trial • 54 patients with 60 vertebral metastases • No exclusion of patients with epidural disease • Fractionated SBRT • SBRT using SIB concept: • 5 x 4 / 7Gy • 10 x 3 / 4.85Gy • Selection of patients with long OS expectancy
ESTRO SBRT 2017 - Matthias Guckenberger
07.09.17
34
/
Made with FlippingBook Annual report